These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 7152425

  • 1. [Changes in lymphocytes caused by aldosterone and a spironolactone derivative. Animal experiments and clinical studies].
    Liebich HG, Mertin J, Seifert J.
    Fortschr Med; 1982 Nov 04; 100(41):1922-5. PubMed ID: 7152425
    [Abstract] [Full Text] [Related]

  • 2. Spirolactones: clinical and pharmacologic studies.
    Corvol P, Claire M, Rafestin-Oblin ME, Michaud A, Roth-Meyer C, Menard J.
    Adv Nephrol Necker Hosp; 1977 Nov 04; 7():199-215. PubMed ID: 208407
    [No Abstract] [Full Text] [Related]

  • 3. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM, Chinn LJ, Pedrera HA, Krupnick MI, Suleymanov OD.
    J Pharmacol Exp Ther; 1975 Aug 04; 194(2):450-6. PubMed ID: 1151770
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Plasma digoxin radioimmunoassay in patients treated with potassium canrenoate and spironolactone. A comparison of two commerical kits.
    Cristodorescu R, Gavrilescu S, Deutsch G, Berger E.
    Agressologie; 1978 Aug 04; 19(6):409-14. PubMed ID: 751526
    [No Abstract] [Full Text] [Related]

  • 6. The role of potassium-canrenoate on 3H-noradrenaline uptake and metabolism of the rat heart.
    Préda I, Sebeszta M, Harsányi A, Szabó G, Antalóczy Z.
    Acta Physiol Acad Sci Hung; 1978 Aug 04; 51(4):393-9. PubMed ID: 754480
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sodium excretion and sodium-free volume expansion in dogs: effect of inhibition of aldosterone activity by canrenoate.
    Bie P.
    Acta Physiol Scand; 1976 Oct 04; 98(2):272-4. PubMed ID: 983738
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effect of oral spironolactone and intravenous canrenoate-K on the digoxin radioimmunoassay.
    Lichey J, Schröder R, Rietbrock N.
    Int J Clin Pharmacol Biopharm; 1977 Dec 04; 15(12):557-9. PubMed ID: 598949
    [Abstract] [Full Text] [Related]

  • 12. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S, Buch J.
    Eur J Cardiol; 1979 Aug 04; 10(2):143-9. PubMed ID: 477703
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The role of potassium-canrenoate in the 3H-noradrenaline uptake and metabolism of the rat heart.
    Préda I, Sebeszta M, Antalóczy Z.
    Arzneimittelforschung; 1980 Aug 04; 30(3):436-8. PubMed ID: 7387752
    [Abstract] [Full Text] [Related]

  • 17. Clinical study of potassium canrenoate on raised intracranial pressure.
    Node Y, Nakazawa S.
    Adv Neurol; 1990 Aug 04; 52():557. PubMed ID: 2396562
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A, Tso G, Wells A.
    Ther Drug Monit; 2008 Dec 04; 30(6):744-7. PubMed ID: 18824952
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.